References
- Safar Zadeh E, Lungu AO, Cochran EK et al. The liver diseases of lipodystrophy: The long-term effect of leptin treatment. J. Hepatol. 59, 131–137 (2013).
- Javor ED, Ghany MG, Cochran EK et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 41, 753–760 (2005).
- Moon HS, Dalamaga M, Kim SY et al. Leptin’s role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr. Rev. 34(3), 377–412 (2013).
- Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J. Hepatol. 45, 600–606 (2006).
- Fiorenza CG, Chou SH, Mantzoros CS. Lipodystrophy: pathophysiology and advances in treatment. Nat. Rev. Endocrinol. 7, 137–150 (2011).
- Cartwright BR, Goodman JM. Seipin: from human disease to molecular mechanism. J. Lipid. Res. 53, 1042–1055 (2012).
- Oral EA, Simha V, Ruiz E, Andewelt A et al. Leptin-replacement therapy for lipodystrophy. N. Engl. J. Med. 346, 570–578 (2002).
- Chan JL, Lutz K, Cochran E et al. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr. Pract. 17, 922–932 (2011).
- Takahashi Y, Soejima Y, Fukusato T. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J. Gastroenterol. 18, 2300–2308 (2012).
- Savage DB. Mouse models of inherited lipodystrophy. Dis. Model. Mech. 2, 554–562 (2009).
- Simha V, Subramanyam L, Szczepaniak L et al. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. J. Clin. Endocrinol. Metab. 97, 785–792 (2012).
- Aleffi S, Petrai I, Bertolani C et al. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 42, 1339–1348 (2005).
- Cao Q, Mak KM, Lieber CS. Leptin represses matrix metalloproteinase-1 gene expression in LX2 human hepatic stellate cells. J. Hepatol. 46, 124–133 (2007).
- Choi SS, Syn WK, Karaca GF et al. Leptin promotes the myofibroblastic phenotype in hepatic stellate cells by activating the hedgehog pathway. J. Biol. Chem. 285, 36551–36560 (2010).
- Ikejima K, Okumura K, Kon K, Takei Y, Sato N. Role of adipocytokines in hepatic fibrogenesis. J. Gastroenterol. Hepatol. 22(Suppl. 1), S87–S92 (2007).
- Heymsfield SB, Greenberg AS, Fujioka K et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA. 282, 1568–1575 (1999).
- Hukshorn CJ, Saris WH, Westerterp-Plantenga MS, Farid AR, Smith FJ, Campfield LA. Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J. Clin. Endocrinol. Metab. 85, 4003–4009 (2000).
- Mittendorfer B, Horowitz JF, DePaoli AM, McCamish MA, Patterson BW, Klein S. Recombinant human leptin treatment does not improve insulin action in obese subjects with Type 2 diabetes. Diabetes 60, 1474–1477 (2011).
- Roth JD, Roland BL, Cole RL et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc. Natl Acad. Sci. USA 105, 7257–7262 (2008).
- Ravussin E, Smith SR, Mitchell JA et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity 17, 1736–1743 (2009).